Jetcraft Releases 5-year Pre-Owned Market Forecast Enriched With Customer Insights
17.11.2020 15:00:00 EET | Business Wire | Press release
Jetcraft, the world leader in business jet sales and acquisitions, is releasing a 5-Year Pre-Owned Business Aviation Market Forecast – including, for the first time, trends from the company’s own past transactional data and customer insights.
The latest forecast predicts pre-owned transaction volume and value will recover to steady growth during the five-year period, in spite of the challenges this year, reaching 2,271 transactions worth $11.1B annually by 2024.
Jahid Fazal-Karim, Owner and Chairman of the Board at Jetcraft, says: “Covid-19 has affected many industries, including our own. However, business aviation has started to recover and the reduction in commercial flight activity provides a real opportunity for the sector to further expand its customer base and secure long-term prosperity.
“For this year’s forecast we’ve decided to focus our predictions solely on the pre-owned market, a particular area of strength for Jetcraft and one that isn’t often included in other industry reports. Our forecast shows business aviation has begun to stabilize from the effect of the pandemic, and we expect to see 10,183 pre-owned transactions worth $48.8B in value over the next five years.”
Jetcraft’s forecast highlights trends in international trade activity that bode well for industry growth. Despite temporarily reduced activity in 2020, the World Trade Organization projects trade volume will rebound in 2021. Another key driver in business aviation transactions is the increase in the number of ultra-high net worth individuals (UHNWIs), which is set to grow by 5% per annum until 2024.
Fazal-Karim continues: “Our previous forecasts predicted a downturn. Although it has taken place sooner than we thought, we were prepared and, as a result, are in a stronger position than in 2008. We have seen our industry quickly regain momentum and I’m confident in its recovery, particularly with more first-time buyers realizing the value of business aviation, and the addition of new platforms which continue to improve accessibility.”
Drawing upon nearly 60 years of industry knowledge, this is the first year that Jetcraft’s Market Forecast is incorporating past transactional data and customer insights, delivering a unique look at buyer behavior.
Fazal-Karim concludes: “We are forecasting a continued increase in Large Jet transactions, albeit at a slower pace than in previous years. Our Jetcraft transactional data shows Large Jets representing a strong share of purchases by younger buyers, and that High Net Worth buyer types, as compared to Corporate or Government buyer types, are more likely to invest in this aircraft segment. These trends truly demonstrate the potential of the Large Jet category, which remains poised for long-term growth.
“Predicting the future is certainly more challenging against the backdrop of the current climate, and I’m especially proud to be sharing our anticipated annual industry outlook again this year.”
Jetcraft’s complete 2020 5-year Pre-Owned Business Aviation Market Forecast is available to download at https://www.jetcraft.com/knowledge/market-forecast/.
ENDS
Report graphs, high-resolution images and interviews are available on request.
About Jetcraft
Jetcraft is the leader in international aircraft sales, marketing and ownership strategies, managing and maintaining over 20 regional offices globally. The company’s unparalleled success over more than 55 years in business aviation has earned it a world-class reputation, along with an exceptional customer base, a wide network of connections and one of the largest inventories within the industry.
For more information, please visit www.jetcraft.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201117005566/en/
Contact information
8020 Communications.
E-Mail: jetcraft@8020comms.com
Telephone: +44 (0)1483 447380
Michaela Wilkins
Email: mwilkins@8020comms.com
Telephone: +44 (0) 1483 366419.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release
Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila
PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
